Targeted therapy in oncology: mechanisms and toxicity
Steeghs, N.
Citation
Steeghs, N. (2009, November 24). Targeted therapy in oncology:
mechanisms and toxicity. Retrieved from https://hdl.handle.net/1887/14431
Version: Corrected Publisher’s Version
License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from: https://hdl.handle.net/1887/14431
Note: To cite this publication please use the final published version (if
applicable).
Targeted therapy in oncology:
mechanisms and toxicity
Neeltje Steeghs
Targeted therapy in oncology: mechanisms and toxicity
ISBN/EAN: 978-90-9024614-7
Lay-out: Grafisch bureau Christine van der Ven, Voorschoten Printed by: Gildeprint Drukkerijen, Enschede
Financial support for printing this thesis by SKOL (Stichting Klinische Oncologie Leiden), AZL Onderzoeks- en Ontwikkelingskrediet Apotheek, Abbott, Amgen, Astra Zeneca, Bayer Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Janssen-Cilag, Merck, Merck Sharp & Dohme, Nerviano MS, Novartis, Pfizer, Sanofi-Aventis, and Wyeth is gratefully acknowledged
© 2009 Neeltje Steeghs, Leiderdorp, The Netherlands
Targeted therapy in oncology:
mechanisms and toxicity
Proefschrift
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. P.F. van der Heijden, volgens besluit van het College voor Promoties
te verdedigen op dinsdag 24 november 2009 klokke 15.00 uur
door
Neeltje Steeghs
geboren te Breda in 1977
PROMOTIECOMMISSIE
Promotores: Prof. Dr. J.W.R. Nortier Prof. Dr. H.-J. Guchelaar
Copromotor: Dr. A.J. Gelderblom
Leden: Prof. Dr. M. Danhof Prof. Dr. A.J. Rabelink Prof. Dr. J.H.M. Schellens
CONTENTS
Chapter 1 General introduction and outline of the thesis ...
Chapter 2 Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments ...
Ann Surg Oncol. 2007 Feb;14(2):942-53
Chapter 3 EGFR and ERBB2 expression in sarcomas: the search for new
treatment options. ...
Chapter 4 A phase I dose escalation study of telatinib (BAY 57-9352), a tyrosine kinase inhibitor of VEGFR-2, VEGFR-3, PDGFR-β and c-Kit, in patients with advanced or metastatic solid tumors ...
J Clin Oncol. 2009;27(15): 4188–4196.
Chapter 5 Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors ...
Submitted
Chapter 6 Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor ...
Clin Cancer Res. 2008 Jun 1;14(11):3470-6
Chapter 7 Reversibility of capillary density after discontinuation of bevacizumab treatment ...
Ann Oncol, in press
Chapter 8 Phase I dose escalation study of sunitinib in combination with ifosfamide ...
Study ongoing
Chapter 9 A phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor PHA-739358 in patients with advanced or metastatic solid tumors ...
J Clin Oncol, in press
7
13
35
45
63
75
93
107
125
Chapter 10 Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor PHA-739358 ...
Submitted
Chapter 11 General discussion ...
Summary ...
Samenvatting ...
Nawoord ...
Curriculum vitae ...
Publications ...
145
161
167
173
179
183
187
